Interleukin-2 in Association with Increasing Doses of Interferon-Gamma in Patients with Advanced Cancer

Journal of Immunotherapy

Volumn 11, Issue 3, 1992, Pages 218-224

  Viens, P ^a   Blaise, D ^a   Stoppa, A M ^a   Brandely, M ^c   Baume, D ^a   Olive, D ^a   Resbeut, M ^a   Delpero, J R ^b   Lopez, M ^a   Aubert, C ^a   Ayme, Y ^b   Hans, D ^b   Bressac, C ^a   Favre, R ^a   Maraninchi, D ^a  

^a INSERM   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c SANOFI   (France)

Author keywords

Interferongamma; Interleukin 2

Indexed keywords

ALBUMIN; DOPAMINE; FUROSEMIDE; GAMMA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2; RU 49637; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; DRUG THERAPY; FEMALE; FLUID RETENTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; PREVENTION; PRIORITY JOURNAL; SIDE EFFECT;

ADOLESCENT; ADULT; BIOLOGICAL RESPONSE MODIFIERS; DRUG EVALUATION; FEMALE; HUMAN; INTERFERON-GAMMA, RECOMBINANT; INTERLEUKIN-2; MALE; MIDDLE AGE; NEOPLASMS; RECOMBINANT PROTEINS; REMISSION INDUCTION; SUPPORT, NON-U.S. GOV'T;

EID: 0026523685     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199204000-00009     Document Type: Article

References (32)

1. Watson J, Mochizuki DY. Interleukin-2: a class of T cell growth factors. Immunol Rev 1980;51:257-78.
2. Henney CS, Kuribayashi K, Kern DE. Interleukin-2 augments natural killer cell activity. Nature 1981;291:335-8.
3. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lym-phokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by IL2 activated au-tologous human peripheral blood lymphocytes. Exp Med 1982;155:1823-41.
4. Thompson J, Peace D, Klarnet J, Kern D, Greenberg P, Cheever M. Eradication of disseminated murine leukemia with high-dose Interleukin-2. J Immunol 1986;137:3675-80.
5. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukine 2 or high-dose interlukine 2 alone. N Engl J Med 1987;316:889-97.
6. Rosenberg SA. Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells. In: De Vita V, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: Lippincott, 1988:217-57.
7. Steeg PS, Moore RN, Johnson HM, Oppenheim JJ. Regulation of murine macrophage Ia antigen expression by a lymphokine with immune interferon activity. J Exp Med 1982; 156:1780-93.
8. Gerrard TL, Dyer DR, Zoon KC, Nedden DZ, Siegel JP. Modulation of class I and class II histocompatibility antigens on human T cell lines by IFN gamma. J Immunol 1988;140: 3450-5.
9. Johnson M, Farrar W. The role of a gamma interferon like lymphokine in the activation of T cells for expression of Interleukin-2 receptors. Cell Immunol 1985;75:154-9.
10. Rambaldi A, Young D, Herrmann F, Cannistra S, Griffin J. Interferon induces expression of the Interleukin-2 receptor gene in human monocytes. Eur J Immunol 1987;17:153-6.
11. Foon KA, Sherwin SA, Abrams PG. A phase I trial of re-combinant gamma interferon in patients with cancer. Cancer Immunol Immunother 1985;20:193-7.
12. Kuzrock RM, Rosemblum MG, Sherwin SA, et al. Pharma-cokinetics, single dose tolerance, and biological activity of recombinant gamma interferon in cancer patients. Cancer Res 1985;45:2866-72.
13. Vadhan-Raj S, Katib AL, Bhalla R, et al. Phase I trial of recombinant interferon gamma in cancer patients. J Clin Oncol 1986;4:137-46.
14. Rinehart JJ, Malspeis I, Young D, et al. Phase I-II trial of recombinant interferon gamma in renal cell carcinoma. J Biol Response Mod 1986;5:300-8.
15. Grups JW, Frohmüller GW. Cyclic interferon gamma treatment of patients with metastatic renal carcinoma. Br J Urol 1989;64:218-20.
16. Pujade-Lauraine E, Colombo N, Namer M, et al. Intraperi-toneal human r-IFN gamma in patients with residual ovarian carcinoma at second look laparotomy [Abstract]. Proc Am Soc Clin Oncol 1990;9:603.
17. Shalaby R, Svedersky L, Mackay P, Finckle B, Paladino M. In vivo augmentation of natural killer activity by combined treatment with recombinant gamma interferon and interleu-kin 2. J Interferon Res 1985;5:571-81.
18. Mackawa R, Kitagawa T, Hojo K, Sato K. Differential effi- cacies of recombinant murine gamma interferon and recom-binant human interleukin-2 against EL4-bearing mice. J Interferon Res 1988;8:241-9.
19. Silagi S, Dutkowski R, Schaeffer A. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon gamma. Int J Cancer 1988;41:315-22.
20. Blaise D, Stoppa AM, Brandely M, et al. Sequential bolus administration of rIL2 (RU 49637) in treatment of advanced solid malignancies. In: Freund M, Link H, Welte K, eds. Cytokines in hemopoiesis, oncology and AIDS. Berlin, Heidelberg: Springer-Verlag, 1990:673-81.
21. WHO Handbook for reporting results of cancer treatment. Geneva, WHO Offset Publication 48, 1980.
22. Quesada JR, Talpaz M, Rios A, Kuzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986;4:234-43.
23. Belldegrun A, Webb DE, Austin HA, III, et al. Effects of Interleukin-2 on renal function in patients receiving immu-notherapy for advanced cancer. Ann Intern Med 1987;106: 817-22.
24. Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with Interleukin-2. J Clin Oncol 1989;7:7-20.
25. Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsy-chiatric effects of treatment with Interleukin-2 and lympho-kine activated killer cells. Ann Intern Med 1987;4107:293-300.
26. Fisher B, Keenan AM, Garra BS, et al. Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. J Clin Oncol 1989;7:1852-62.
27. Lee KH, Talpaz M, Rothberg JM, et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha 2A in cancer patients: a phase I study. J Clin Oncol 1989;7:1726-32.
28. Rosenberg SA, Lotze MT, Yang JL, et al. Combination therapy with interleukin-2 and alpha interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-74.
29. Wagstaff J, Vermorken JB, Schartsmann G, et al. A progress report of a phase I study of Interferon gamma and interleukin-2 and some comments on the mechanism of the toxicity due to interleukin-2. Cancer Treat Rev 1989;16(Suppl A):105-9.
30. Kleinerman ES, Kurzrock R, Wyatt D. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma interferon. Cancer Res 1986;46:5401-5.
31. Maluish AE, Urba WJ, Longo DL, et al. The determination of an immunologically active dose of interferon gamma in patients with melanoma. J Clin Oncol 1988;6:434-45.
32. Aulitzky W, Gastil G, Aulitzky WE, et al. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon gamma. J Clin Oncol 1989;7:1875-84.